Arvinas Announces Results from the VERITAC-2 Trial Selected as Late-Breaking Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Arvinas (NASDAQ: ARVN) announced that results from its Phase 3 VERITAC-2 clinical trial will be presented as a late-breaking oral presentation at the 2025 ASCO Annual Meeting in Chicago. The presentation will reveal the first pivotal data for vepdegestrant, a potential first-in-class oral PROTAC estrogen receptor degrader, being developed jointly with Pfizer.
The trial evaluated vepdegestrant versus fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The presentation, scheduled for May 31, 2025, will be delivered by Dr. Erika P. Hamilton from the Sarah Cannon Research Institute's Breast Cancer Research Program.
Arvinas (NASDAQ: ARVN) ha annunciato che i risultati del suo studio clinico di Fase 3 VERITAC-2 saranno presentati come comunicazione orale di rilievo durante il 2025 ASCO Annual Meeting a Chicago. La presentazione svelerà i primi dati fondamentali su vepdegestrant, un potenziale degrader orale del recettore degli estrogeni PROTAC di prima classe, sviluppato in collaborazione con Pfizer.
Lo studio ha confrontato vepdegestrant con fulvestrant in pazienti con cancro al seno avanzato o metastatico ER+/HER2-. La presentazione, prevista per il 31 maggio 2025, sarà tenuta dalla Dott.ssa Erika P. Hamilton del Breast Cancer Research Program del Sarah Cannon Research Institute.
Arvinas (NASDAQ: ARVN) anunció que los resultados de su ensayo clínico de Fase 3 VERITAC-2 se presentarán en una ponencia oral de última hora en la Reunión Anual ASCO 2025 en Chicago. La presentación revelará los primeros datos clave sobre vepdegestrant, un posible degradador oral del receptor de estrógenos PROTAC de primera clase, desarrollado conjuntamente con Pfizer.
El ensayo evaluó vepdegestrant frente a fulvestrant en pacientes con cáncer de mama avanzado o metastásico ER+/HER2-. La presentación, programada para el 31 de mayo de 2025, será impartida por la Dra. Erika P. Hamilton del Programa de Investigación del Cáncer de Mama del Sarah Cannon Research Institute.
Arvinas (NASDAQ: ARVN)는 시카고에서 열리는 2025 ASCO 연례 회의에서 3상 VERITAC-2 임상시험 결과를 긴급 구두 발표로 공개할 것이라고 발표했습니다. 이번 발표에서는 Pfizer와 공동 개발 중인 잠재적 최초 경구용 PROTAC 에스트로겐 수용체 분해제인 vepdegestrant의 첫 중추적 데이터가 공개됩니다.
이번 임상시험은 ER+/HER2- 진행성 또는 전이성 유방암 환자에서 vepdegestrant와 풀베스트란트를 비교 평가했습니다. 발표는 2025년 5월 31일 Sarah Cannon 연구소 유방암 연구 프로그램의 에리카 P. 해밀턴 박사가 진행할 예정입니다.
Arvinas (NASDAQ : ARVN) a annoncé que les résultats de son essai clinique de phase 3 VERITAC-2 seront présentés lors d'une communication orale de dernière minute au Congrès annuel ASCO 2025 à Chicago. Cette présentation dévoilera les premières données clés sur le vepdegestrant, un dégradeur oral du récepteur des œstrogènes PROTAC potentiellement de première classe, développé conjointement avec Pfizer.
L’essai a comparé le vepdegestrant au fulvestrant chez des patientes atteintes d’un cancer du sein avancé ou métastatique ER+/HER2-. La présentation, prévue le 31 mai 2025, sera assurée par le Dr Erika P. Hamilton du Breast Cancer Research Program du Sarah Cannon Research Institute.
Arvinas (NASDAQ: ARVN) gab bekannt, dass die Ergebnisse seiner Phase-3-VERITAC-2-Studie als kurzfristige mündliche Präsentation auf dem ASCO-Jahrestreffen 2025 in Chicago vorgestellt werden. Die Präsentation wird die ersten entscheidenden Daten zu vepdegestrant zeigen, einem potenziellen oralen PROTAC-Estrogenrezeptor-Degrader erster Klasse, der gemeinsam mit Pfizer entwickelt wird.
Die Studie verglich vepdegestrant mit Fulvestrant bei Patientinnen mit ER+/HER2- fortgeschrittenem oder metastasiertem Brustkrebs. Die Präsentation, die für den 31. Mai 2025 geplant ist, wird von Dr. Erika P. Hamilton vom Breast Cancer Research Program des Sarah Cannon Research Institute gehalten.
- First-in-class potential for vepdegestrant in breast cancer treatment
- Partnership with major pharmaceutical company Pfizer
- Selection for late-breaking presentation at prestigious ASCO conference
- None.
– Oral presentation will serve as first presentation of detailed results from the Phase 3 VERITAC-2 clinical trial –
NEW HAVEN, Conn., April 23, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that data from the global Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant versus fulvestrant in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer will be presented as a late-breaking oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 – June 3 in Chicago, IL. The presentation includes the first pivotal data for vepdegestrant, a potential first-in-class investigational oral PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader.
Vepdegestrant is being jointly developed by Arvinas and Pfizer for the treatment of patients with advanced or metastatic ER+/HER2- breast cancer.
Presentation details are as follows:
Title: Vepdegestrant, a PROTAC estrogen receptor (ER) degrader, vs. fulvestrant in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC): results of the global, randomized, phase 3 VERITAC-2 study
Presenting Author: Erika P. Hamilton, MD, Breast Cancer Research Program, Sarah Cannon Research Institute
Abstract Number: LBA1000
Session Date, Time and Location: Saturday, May 31, 2025, 1:15 PM-4:15 PM CT in Hall B1
Session Type and Title: Oral Abstract Session – Breast Cancer—Metastatic
Late-breaking abstracts will be released at 7:00 am CT / 8:00 am ET on the day of the scientific presentation. Additional information can be found at www.asco.org.
About Vepdegestrant
Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER) for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) breast cancer. Vepdegestrant is being developed as a potential monotherapy and as part of combination therapy across multiple treatment settings for ER+/HER2- metastatic breast cancer.
In July 2021, Arvinas announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant; Arvinas and Pfizer will share worldwide development costs, commercialization expenses, and profits.
The U.S. Food and Drug Administration (FDA) has granted vepdegestrant Fast Track designation as a monotherapy in the treatment of adults with ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC (PROteolysis TArgeting Chimera) protein degrader platform, the Company is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin Lymphoma; and ARV-102, targeting LRRK2 for neurodegenerative disorders. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: vepdegestrant having the potential to provide clinically meaningful outcomes for thousands of patients with metastatic breast cancer whose tumors harbor estrogen receptor 1 mutations; Arvinas’ and Pfizer’s plans to share data from the Phase 3 VERITAC-2 clinical trial with health authorities, including to potentially support regulatory filings, as well as at medical conferences in 2025; and vepdegestrant’s development as a potential monotherapy and as part of combination therapy across multiple treatment settings for estrogen receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “target,” “goal,” “potential,” “will,” “would,” “could,” “should,” “look forward,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration between Arvinas and Pfizer; whether Arvinas and Pfizer will be able to successfully conduct and complete clinical development for vepdegestrant as a monotherapy and as part of combination therapy; whether Arvinas will be able to successfully conduct and complete development for its other product candidates, including ARV-393 and ARV-102; whether Arvinas and Pfizer, as appropriate, will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all; Arvinas’ ability to protect its intellectual property portfolio; Arvinas’ reliance on third parties; whether Arvinas will be able to raise capital when needed; whether Arvinas’ cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.
Contacts
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
What are the key findings from Arvinas' VERITAC-2 Phase 3 trial for vepdegestrant (ARVN)?
How does vepdegestrant differ from existing breast cancer treatments?
What is the partnership status between Arvinas and Pfizer for vepdegestrant?
When will Arvinas present the VERITAC-2 trial results at ASCO 2025?
